<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVE: Patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t, or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and abnormalities involving chromosomes 5 and/or 7 (-5, -7) generally, but not always, have poorer prognoses than patients with a <z:mpath ids='MPATH_458'>normal</z:mpath> karyotype </plain></SENT>
<SENT sid="1" pm="."><plain>Our objective was to see whether the occasional relatively favorable outcome in -5/-7 patients is a random event or, rather, reflects true <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> in -5/-7 </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN AND METHODS: We examined 3 factors known to be prognostic in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> for their prognostic significance in 400 -5/-7 patients treated at the M.D </plain></SENT>
<SENT sid="3" pm="."><plain>Anderson <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Center from 1980-1998 for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The outcome of comparative interest was survival as assessed by log-rank test </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: There was evidence that outcome was better in -5/-7 patients with a simple (rather than complex) karyotype, with &gt; 1 <z:mpath ids='MPATH_458'>normal</z:mpath> metaphase (rather than only metaphases containing -5/-7), and without an antecedent <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorder</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>More importantly, the 10% of the patients with a simple karyotype, &gt; 1 <z:mpath ids='MPATH_458'>normal</z:mpath> metaphase, and no antecedent <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorder</z:e> not only had a better outcome than the other -5/-7 patients but had essentially identical outcomes to the 669 AML/MDS patients with a <z:mpath ids='MPATH_458'>normal</z:mpath> karyotype treated at M.D </plain></SENT>
<SENT sid="7" pm="."><plain>Anderson during the same period </plain></SENT>
<SENT sid="8" pm="."><plain>INTERPRETATION AND CONCLUSIONS: The results indicate that the -5/-7 group should not a priori be regarded as having an unfavorable prognosis, and more generally suggest the need to refine prognosis within each of the cytogenetic subsets of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>